Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Neurizon Therapeutics Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Sergio Duchini Date of last notice 8 November 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct & Indirect Nature of indirect interest (including registered holder) Kelbury Pty Ltd Note: Provide details of the circumstances giving rise to the relevant interest. Mr Duchini is a Director of the above holder which is the registered holder of the securities Date of change 31 January 2025 No. of securities held prior to change Indirect 1,315,789 fully paid ordinary shares Class Unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Number acquired 960,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Number disposed - Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Indirect 1,315,789 fully paid ordinary shares Direct 960,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Grant of unlisted options as approved by shareholders at the Company’s Annual General Meeting held on 9 October 2024, pursuant to Resolution 12(a). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to N/A which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts No detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow N/A the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Neurizon Therapeutics Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Kathryn MacFarlane Date of last notice 8 November 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 31 January 2025 No. of securities held prior to change 263,158 fully paid ordinary shares Class Unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Number acquired 600,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Number disposed - + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nil 263,158 fully paid ordinary shares 600,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Grant of unlisted options as approved by shareholders at the Company’s Annual General Meeting held on 9 October 2024, pursuant to Resolution 12(c). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to N/A which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts No detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow N/A the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Neurizon Therapeutics Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Marcus Hughes Date of last notice 8 November 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct and Indirect Nature of indirect interest (including registered holder) Mr Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> Note: Provide details of the circumstances giving rise to the relevant interest. Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities Ms Antoinette Quinlan Spouse of Marcus Hughes Date of change 31 January 2025 + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held prior to change Direct - 11,944,079 fully paid ordinary shares Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> - 2,085,895 fully paid ordinary shares Indirect – Ms Antoinette Quinlan - 423,895 fully paid ordinary shares Class Unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Number acquired 600,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Number disposed - Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Direct - 11,944,079 fully paid ordinary shares - 600,000 unlisted options, exercisable at $0.20 (20 cents) each, expiring 30 June 2032 Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> - 2,085,895 fully paid ordinary shares Indirect – Ms Antoinette Quinlan - 423,895 fully paid ordinary shares + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Grant of unlisted options as approved by shareholders at the Company’s Annual General Meeting held on 9 October 2024, pursuant to Resolution 12(b). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to N/A which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts No detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow N/A the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3